March 10 (Reuters) - Trevi Therapeutics Inc TRVI.O:
TREVI THERAPEUTICS INC: HADUVIO MET PRIMARY ENDPOINT
TREVI THERAPEUTICS: ANNOUNCE POSITIVE TOPLINE RESULTS FROM ITS PHASE 2A RIVER TRIAL OF HADUVIO FOR TREATMENT OF PATIENTS WITH RCC (N=66)
TREVI THERAPEUTICS: PATIENT REPORTED & OTHER SECONDARY OUTCOMES WERE STATISTICALLY SIGNIFICANT & CONSISTENT WITH PRIMARY ENDPOINT